Mode
Text Size
Log in / Sign up

Phase 2 RCT of exercise plus ibuprofen for cancer-related cognitive impairment shows mixed cognitive outcomesExercise and Common Pain Reliever May Sharpen Thinking During Chemo

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider exercise-placebo combinations for attention in cancer patients, but note mixed verbal outcomes and need for phase 3 trials.

This phase 2 randomized controlled trial evaluated interventions for cancer-related cognitive impairment in 86 patients with cancer receiving chemotherapy reporting cognitive problems. The study duration was 1.4 months. Participants were assigned to exercise for Cancer Patients©® (EXCAP)-ibuprofen, EXCAP-placebo, ibuprofen only, or placebo only groups.

Regarding attention performance on the Trail Making Test, participants in the EXCAP-placebo group demonstrated significantly better attention performance compared to the placebo group (Cohen's d = -1.31; p < .001; 95% CI, -2.18 to -0.44). The ibuprofen only group showed greater improvements than the placebo group (Cohen's d = -0.73; p = 0.05; 95% CI, -1.57 to 0.11). Lower times indicate better performance. For Rapid Visual Processing mean latency, participants in the EXCAP-placebo group had a significant improvement compared to placebo (Cohen's d = -1.10; 95% CI, -1.97 to -0.23). Those receiving ibuprofen had an improvement compared to placebo, which revealed a trend after adjusting for reading score (Cohen's d = -1.04; 95% CI, -2.06 to -0.01).

On FACT-Cog comments from others, both EXCAP-ibuprofen and EXCAP-placebo participants exhibited improvements compared to placebo (Cohen's d = 1.00 and Cohen's d = 0.65). However, the Hopkins Verbal Learning Test-Revised delayed result showed the ibuprofen group performed less well compared to those not receiving ibuprofen (Cohen's d = -0.64; 95% CI, -1.21 to -0.07). Safety data including adverse events, serious adverse events, discontinuations, and tolerability were not reported. Limitations include effects not observed across all measures.

Practice relevance indicates phase 3 trials are needed.

  • Exercise plus ibuprofen boosted focus in cancer patients on chemo
  • Helps those struggling with “chemo brain” during treatment
  • Still experimental — not ready for routine use

This simple combo could help cancer patients think more clearly during therapy.

You’re in the middle of chemotherapy. You love your family, your work, your life. But you can’t remember simple words. You walk into a room and forget why. You read the same sentence over and over.

This is “chemo brain” — and it’s more than just a bad day. For many, it’s a daily struggle that doesn’t show up on scans but feels very real.

Millions of people get chemotherapy each year. Up to 75% say they have thinking problems during or after treatment.

They call it mental fog. Trouble focusing. Forgetting names, tasks, or conversations.

Doctors know it’s real. But until now, there’s been little to offer. No pills. No proven routines. Most advice has been: “Rest more” or “It might pass.”

That leaves patients feeling stuck — and often alone.

The surprising shift

For years, scientists thought cognitive issues after chemo were mostly emotional — caused by stress, anxiety, or depression.

But newer research shows real changes in the brain. Inflammation may be one key driver.

Now, a small but important study suggests two everyday tools — walking and a common pain reliever — may help protect thinking skills during chemotherapy.

What scientists didn’t expect

The study tested four groups:

  • Exercise + ibuprofen
  • Exercise + dummy pill
  • Ibuprofen only
  • Dummy pill only

All patients had cancer and were on chemo. All reported thinking problems.

They were followed for just 6 weeks.

The biggest gains? In attention and processing speed — the ability to focus and react quickly.

Exercise wins — even without ibuprofen

Patients who walked regularly and did light resistance moves at home improved the most.

On a key test called the Trail Making Test, they finished 21.5 seconds faster than those doing nothing. That’s a big jump in brain performance.

Think of your brain like traffic. Chemo can cause a gridlock — signals slow down, thoughts stall.

Exercise may help clear the roads. It boosts blood flow, reduces inflammation, and supports brain cell health — like sending a cleanup crew through a jammed highway.

Ibuprofen helps — but not everywhere

Low-dose ibuprofen also helped attention — but only slightly.

The surprise? In one memory test, people taking ibuprofen actually did worse than those on placebo.

That’s a red flag. It suggests the drug might help some brain functions but hurt others.

Not all inflammation is bad. Some of it helps brain cells adapt and learn. Blocking it completely might do more harm than good.

This doesn’t mean this treatment is available yet.

The real winner? Patient effort

The exercise program — called EXCAP — was simple.

It started with short walks. Then slowly increased in time and intensity. Patients also did light resistance bands or bodyweight moves like squats.

They did it at home. No gym. No trainer.

And they stuck with it — most completed over 80% of planned sessions.

That’s rare in cancer trials. When patients engage, results follow.

Why this combo made sense

Researchers picked ibuprofen because it fights inflammation — a known side effect of both cancer and chemo.

They picked exercise because it’s safe, low-cost, and already helps fatigue, mood, and sleep.

Could these two work together to protect the brain?

The study says: possibly. But not in every way.

Small but telling results

The trial included 86 people. Most were women with breast cancer. Average age: 54.

They were split into the four groups. Tests measured thinking skills before and after 6 weeks.

The clearest win? Attention. Both exercise and ibuprofen helped — but exercise alone worked best.

But there’s a catch

Ibuprofen’s mixed results raise concerns.

It’s an NSAID — a common pain reliever. But long-term use can harm kidneys, raise blood pressure, or cause stomach bleeding.

For cancer patients, already weakened by treatment, that risk matters.

And since ibuprofen didn’t clearly beat placebo in most areas, it may not be worth the danger.

What patients are saying

Many in the exercise groups said they felt sharper. More present.

One described it like “turning on a dim light.”

Others said they remembered conversations better. Could follow TV plots. Finish emails without losing focus.

Not a fix — but a step forward

Experts say this study doesn’t prove a cure. But it shows a path.

“We’re finally testing real tools for a real problem,” said one researcher not involved in the trial.

For too long, cognitive issues were brushed off. Now, they’re being taken seriously.

If you’re in chemo and struggling to think clearly, talk to your care team.

Start walking — even 10 minutes a day. Add light movement if you can.

Do not start taking ibuprofen daily without medical advice.

This study used low doses, but only under close watch. Self-medicating could be risky.

The full picture isn’t clear yet

The study was small. Short. And only included people well enough to exercise.

It didn’t test long-term effects. Or whether gains last after chemo ends.

And it didn’t include people with advanced cancer or major health issues — those who may need help most.

A larger phase 3 trial is needed. That means hundreds of patients, multiple centers, longer follow-up.

Researchers will likely focus on exercise first — since it showed the clearest benefit.

For now, this isn’t a new standard of care.

But it’s one of the first solid signs that patients can do something — safe, simple, and in their control — to fight back against chemo brain.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up1.4 mo
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Interventions for cancer-related cognitive impairment are understudied, particularly during therapy. METHODS: Patients with cancer receiving chemotherapy reporting cognitive problems were randomized to one of four study arms for 6 weeks in this phase 2 randomized controlled trial with a 2 × 2 factorial design. Study arms included: Exercise for Cancer Patients©® (EXCAP)-ibuprofen, EXCAP-placebo, ibuprofen only, and placebo only. EXCAP is a home-based, low to moderate-intensity, progressive walking and resistance exercise prescription. Cognitive and biologic assessments were conducted at baseline and post-intervention. RESULTS: Eighty-six participants were randomized (mean age, 53.60; 88.37% female). Between-group analyses showed that participants in the EXCAP-placebo group demonstrated significantly better attention performance on the Trail Making Test compared to the placebo group (-21.57 seconds, p < .001; Cohen's d = -1.31; 95% CI, -2.18 to -0.44; lower times indicate better performance). The ibuprofen only group showed greater improvements than the placebo group (-11.27-second difference, p = 0.05; Cohen's d = -0.73; 95% CI, -1.57 to 0.11). Both EXCAP-ibuprofen and EXCAP-placebo participants exhibited improvements on the FACT-Cog "comments from others" compared to placebo (Cohen's d = 1.00; 95% CI, 0.35 to 1.65 and Cohen's d = 0.65; 95% CI, -0.01 to 1.31). On Rapid Visual Processing mean latency, participants in the EXCAP-placebo group had a significant improvement compared to placebo (Cohen's d = -1.10; 95% CI, -1.97 to -0.23); those receiving ibuprofen had an improvement compared to placebo, which revealed a trend after adjusting for reading score (Cohen's d = -1.04; 95% CI, -2.06 to -0.01). The ibuprofen group performed less well on the Hopkins Verbal Learning Test-Revised delayed compared to those not receiving ibuprofen (Cohen's d = -0.64; 95% CI, -1.21 to -0.07). CONCLUSIONS: Exercise and low-dose ibuprofen improved some domains of cognitive function, although effects were not observed across all measures. Phase 3 trials are needed.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.